Product Code: DMPH5210
The global sinusitis treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).
Sinusitis is an inflammatory condition in which the sinuses become blocked and clogged with fluid. The most common causes are colds or allergies. An infection could result from the blockage.
The factors influencing the global sinusitis treatment market are the increasing research and development for sinusitis treatment and the growing prevalence of sinusitis.
The increasing research and development for the treatment of sinusitis are expected to drive the market growth
Chronic sinusitis treatment options include nasal corticosteroids. Inflammation is prevented and treated with these nasal sprays. Fluticasone, triamcinolone, budesonide, mometasone, and beclomethasone are some examples. Nasal irrigation with saline nasal sprays or solutions reduces nasal drainage and flushes out irritants and allergies. Corticosteroids, either oral or injected, are used to treat severe sinusitis inflammation, especially if one has nasal polyps. Because long-term use of oral corticosteroids can have serious side effects, they are only used to treat severe symptoms.
Antibiotics may be required for sinusitis if bacteria cause the infection. If the doctor cannot rule out an infection, they may prescribe an antibiotic combined with other medications. Moreover, endoscopic sinus surgery may be an option in cases where treatment or medication has failed. The doctor will use an endoscope (a thin, flexible tube with a light attached) to examine sinus passages during this procedure. The safety and efficacy of an intranasal treatment for adults with chronic sinusitis with or without nasal polyps are being investigated by researchers at The University of Texas Health Science Center at Houston (UTHealth). XHANCE is a treatment for nasal polyps in adults that have been approved by the US Food and Drug Administration. Experts from McGovern Medical School at UTHealth's Department of Otorhinolaryngology-Head and Neck Surgery hope to find relief for patients with chronic rhinosinusitis as well as the current indication for nasal polyposis in the new study.
Side effects of sinusitis medication are expected to hamper the market growth
The side effects of sinus infection medications vary depending on the medication. The side effects of corticosteroids include dizziness, nausea, indigestion, increased appetite, weight gain, weakness, and sleep disturbances. Drowsiness, heart palpitations, difficulty urinating, constipation, dry mouth, and nervousness are all possible side effects of some antihistamines. According to research, about 90% of adults seen by a general practitioner in the United States receive an antibiotic for acute sinusitis.
An acute sinus infection lasts less than four weeks. Sinusitis that lasts longer than 12 weeks is considered chronic. Viruses or bacteria commonly cause infections of the sinuses, which are hollow air spaces within the bones of the cheekbones, forehead, and between the eyes. They cause thick mucus blockage and cavity discomfort. According to recent research and physician experts, antibiotics may not always be the best treatment for sinusitis. If one has a mild or moderate sinus infection, the body should be able to heal itself without antibiotics, which can lead to antibiotic resistance.
COVID-19 Impact Analysis
The current COVID-19 outbreak is one of the most severe global threats, with far-reaching social and economic consequences. COVID-19 and a sinus infection can cause nasal congestion, fever, and cough. COVID-19 can affect the upper or lower respiratory tract, and inflamed cavities around the nasal passages can be seen in a sinus infection. It is important to know the difference between a sinus infection and COVID-19 because the symptoms are similar. As a result, the sinusitis treatment market is expected to grow in the face of the ongoing pandemic due to increased demand for diagnostic tests and antibiotics.
The antibiotics segment is expected to dominate the market growth
Antibiotics are advised for bacterial sinusitis involving the frontal, sphenoid, or ethmoid sinuses, as this type of sinusitis can cause more serious complications. Antibiotics such as penicillin, cephalosporins, and macrolides have long been recommended. Overuse of antibiotics has led to an increase in antibiotic resistance. According to a report published by the Centers for Disease Control and Prevention in 2019, more than 2.8 million antibiotic-resistant infections occur in the United States each year, resulting in over 35,000 deaths. Although 60% of acute bacterial sinusitis episodes resolve without treatment, antibiotics have consistently been shown to shorten the duration of illness and reduce the frequency of sinusitis complications. Antibiotics are prescribed for acute bacterial sinusitis that lasts more than ten days or worsens after the first week. The most common symptoms are facial pain or pressure, nasal stuffiness or congestion, and thick, discolored nasal drainage.
Antibiotics are frequently prescribed for chronic sinusitis, even though bacteria do not cause many cases. For acute, uncomplicated bacterial sinusitis, amoxicillin remains the drug of choice. Amoxicillin is most effective when given frequently in infected tissue to maintain adequate levels. For patients who are allergic to amoxicillin, azithromycin is an alternative treatment. The main benefit of azithromycin is its ease of use; for acute sinusitis, the recommended treatment is 500 mg once daily for three days. Cephalosporins and Augmentin (amoxicillin with clavulanic acid) are called "broad-spectrum antibiotics" because they are effective against a broader range of bacteria, including those resistant to pen amoxicillin.
North America region is expected to hold the largest market share in the global sinusitis treatment market
The increased research into bacterial and viral diseases and increased awareness in developing countries are expected to contribute to the growth of the sinusitis treatment market in this region.
Sinusitis has a high prevalence rate. In 2019, nearly 26.9 million people in the United States were diagnosed with sinusitis, according to the Centers for Disease Control and Prevention (CDC). Sinusitis is one of the most common reasons for clinical visits in the United States, according to Anne-Julie Tessier et al. 2020, and causes 73 million restricted-activity days over a year. Furthermore, the region's market growth is expected to be fueled by increased health awareness and the active presence of major players. For instance, on 29th July 2021, the US Food and Drug Administration (FDA) approved GlaxoSmithKline plc's Nucala (mepolizumab). This monoclonal antibody targets interleukin-5 (IL-5) as a treatment for patients with chronic rhinosinusitis with nasal polyps. This new indication for mepolizumab is for the maintenance treatment of CRSwNP in adult patients aged 18 and up who have not responded to nasal corticosteroids.
The global sinusitis treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Cipla Ltd., Dr. Reddy's Laboratories Ltd, Sanofi SA, GlaxoSmithKline plc, Pfizer, Inc., Novartis AG, Bayer AG, Jackson Healthcare, Johnson & Johnson, Bayer AG, and others.
- Overview: GlaxoSmithKline is a science-led global healthcare company with a special purpose of improving the quality of human life by helping people do more, feel better, and live longer. It is the world's largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. GlaxoSmithKline pharmaceuticals have a broad portfolio of innovative and established medicines in HIV, respiratory, immuno-inflammation, and oncology.
- Product Portfolio: NUCALA is a prescription maintenance treatment for patients with severe eosinophilic asthma aged 6 and up. NUCALA is not recommended for treating sudden breathing difficulties.
- Key Developments: On 29th July 2021, the US Food and Drug Administration (FDA) approved GlaxoSmithKline plc's Nucala (mepolizumab). This monoclonal antibody targets interleukin-5 (IL-5) as a treatment for patients with chronic rhinosinusitis with nasal polyps. This new indication for mepolizumab is for the maintenance treatment of CRSwNP in adult patients aged 18 and up who have not responded to nasal corticosteroids.
Why Purchase the Report?
- Visualize the composition of the global sinusitis treatment market segmentation by treatment, disease, and distribution channel, highlighting the key commercial assets and players.
- Identify commercial opportunities in global sinusitis treatment market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of global sinusitis treatment market- level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global sinusitis treatment market report would provide an access to an approx. 45+ market data table, 40+ figures and 185 pages.
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
Table of Contents
1. Sinusitis Treatment Market Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Sinusitis Treatment Market- Market Definition and Overview
3. Sinusitis Treatment Market- Executive Summary
- 3.1. Market Snippet By Treatment
- 3.2. Market Snippet By Disease
- 3.3. Market Snippet By Distribution Channel
- 3.4. Market Snippet By Region
4. Sinusitis Treatment Market-Market Dynamics
- 4.1. Market Impacting Factors
- 4.1.1. Drivers:
- 184.108.40.206. The increasing research and development for the treatment of sinusitis
- 4.1.2. Restraints:
- 220.127.116.11. Side effects of sinusitis medication
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
5. Sinusitis Treatment Market- Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Unmet Needs
6. Sinusitis Treatment Market- COVID-19 Analysis
- 6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. Sinusitis Treatment Market- By Treatment
- 7.1. Introduction
- 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
- 7.3. Market Attractiveness Index, By Treatment
- 7.3.1. Antibiotics
- 18.104.22.168.1. Introduction
- 22.214.171.124.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3.2. Analgesics
- 7.3.3. Antihistamines
- 7.3.4. Corticosteroids
- 7.3.5. Surgery
8. Sinusitis Treatment Market-By Disease
- 8.1. Introduction
- 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
- 8.3. Market Attractiveness Index, By Disease
- 8.3.1. Acute Sinusitis
- 126.96.36.199.1. Introduction
- 188.8.131.52.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.3.2. Sub-acute Sinusitis
- 8.3.3. Chronic Sinusitis
9. Sinusitis Treatment Market- By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 9.3. Retail Pharmacies
- 9.4. Other
10. Sinusitis Treatment Market- By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. U.K.
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Sinusitis Treatment Market- Competitive Landscape
- 11.1. Key Developments and Strategies
- 11.2. Company Share Analysis
- 11.3. Product Benchmarking
12. Sinusitis Treatment Market- Company Profiles
- 12.1. GlaxoSmithKline Plc.*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
- 12.2. Cipla Ltd.
- 12.3. Dr. Reddy's Laboratories Ltd
- 12.4. Sanofi SA
- 12.5. Pfizer, Inc.
- 12.6. Novartis AG
- 12.7. Bayer AG
- 12.8. Jackson Healthcare
- 12.9. Johnson & Johnson
- 12.10. Bayer AG
LIST NOT EXHAUSTIVE
13. Sinusitis Treatment Market- DataM
- 13.1. Appendix
- 13.2. About Us and Services
- 13.3. Contact Us